Children diagnosed with arthritis often experience common symptoms like pain, redness, warmth and swelling of the joints. A lot of the time, the symptoms that are associated with these conditions can be debilitating and challenge the day to day lives of children that are affected as well as affect their families.

It is very important to be able to diagnose these conditions quickly and to provide effective treatments in order to prevent further damage to the joints and affected areas. In order to achieve this, we must understand the underlying causes of these conditions, which are yet to be discovered.

One of the biggest challenges when it comes to treating childhood arthritis is providing the correct treatment at the right time. While advanced biologic therapies are often used and can be highly effective, we are currently unable to accurately predict which children should start biologic therapies and which can discontinue treatment without having a disease flare.

The overall goal of the UCAN CAN-DU study is to address this gap in treatment approaches as well as support and advance personalized care for all children with juvenile arthritis.

Our team of researchers believes that studying childhood rheumatic disease is key to providing better patient care, as well as improving quality of life and health outcomes of children suffering with these conditions.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Inclusion criteria:

UCAN CAN-DU is what we call a multicenter longitudinal observational cohort study.

Participants for the study, much like yourself, will be recruited from international teams in Canada and the Netherlands.

There are four main cohorts (groups of people based on certain criteria) in this study. Because of how the study works, you might be eligible for more than one cohort.

If you/your child are ≤18 years of age at time of study enrollment and have or are suspected to have childhood arthritis, you may be eligible for the study.

If you are interested in participating, please talk to your Rheumatologist about the UCAN CAN-DU study!


This study is not currently accepting expressions of interest via the website. Please see contact information below.

Additional information

Contact information

Recruitment for this study is only through referral.

Principal investigator:

Paivi Maria Hannele Miettunen

Clinical trial: